Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation by Stathopoulos, Apostolis et al.
Development of immune memory to glial brain
tumors after tumor regression induced
by immunotherapeutic Toll-like receptor
7/8 activation
Apostolis Stathopoulos,
1,2,* Chrystel Pretto,
2 Laurent Devillers,
2 Denis Pierre,
2 Florence M. Hofman,
2,3 Carol Kruse,
4
Martin R. Jadus,
5,6 Thomas C. Chen
2,8 and Virgil E.J.C. Schijns
2,7,*
1Department of Neurosurgery; Arlon Hospital; Arlon, Belgium;
2Epitopoietic Research Corporation (ERC); Namur, Belgium;
3Department of Pathology; Keck School of Medicine;
University of Southern California; Los Angeles, CA USA;
4Department of Neurosurgery; School of Medicine; University of California; Los Angeles, CA USA;
5Veterans Affairs Medical
Center; Long Beach, CA USA;
6Chao Cancer Center; University of California, Irvine; Orange, CA USA;
7Cell Biology and Immunology Group; Wageningen University; Wageningen,
The Netherlands;
8Department of Neurosurgery; Keck School of Medicine; University of Southern California; Los Angeles, CA USA
Keywords: TLR agonist, brain tumor, glioma, immunotherapy,
The efficacy of immunotherapeutic TLR7/8 activation by resiquimod (R848) was evaluated in vivo, in the CNS-1 rat glioma
model syngeneic to Lewis rats. The immune treatment was compared with cytotoxic cyclophosphamide chemotherapy,
and as well, was compared with the combination cytotoxic and immunotherapeutic treatments. We found that
parenteral treatment with the TLR7/8 agonist, resiquimod, eventually induced complete tumor regression of CNS-1
glioblastoma tumors in Lewis rats. Cyclophosphamide (CY) treatment also resulted in dramatic CNS-1 remission, while
the combined treatment showed similar antitumor effects. The resiquimod efficacy appeared not to be associated with
direct injury to CNS-1 growth, while CY proved to exert tumoricidal cytotoxicity to the tumor cells. Rats that were cured
by treatment with the innate immune response modifier resiquimod proved to be fully immune to secondary CNS-1
tumor rechallenge. They all remained tumor-free and survived. In contrast, rats that controlled CNS-1 tumor growth as a
result of CY treatment did not develop immune memory, as demonstrated by their failure to reject a secondary CNS-1
tumor challenge; they showed a concomittant outgrowth of the primary tumor upon secondary tumor exposure.
Rechallenge of rats that initially contained tumor growth by combination chemo-immunotherapy also failed to reject
secondary tumor challenge, indicating that the cytotoxic effect of the CY likely extended to the endogenous memory
immune cells as well as to the tumor. These data demonstrate strong therapeutic antitumor efficacy for the immune
response modifier resiquimod leading to immunological memory, and suggest that CY treatment, although effective as
chemotherapeutic agent, may be deleterious to maintenance of long-term antitumor immune memory. These data also
highlight the importance of the sequence in which a multi-modal therapy is administered.
Introduction
Glioblastoma multiforme (GBM) is the most common malignant
brain tumor in adult patients. Due to its highly infiltrative nature
GBM is notoriously difficult to treat and complete surgical
resection is difficult. GBM tumors are inevitably recurrent either
locally, close to the original tumor, or at distant sites. Moreover,
chemotherapy and/or radiotherapy have shown only limited
success. As a result the overall prognosis for this tumor has
changed little over the last two decades. Today the average survival
time for a newly diagnosed patient is between 12 and 15 mo and
new forms of therapy are desperately needed to change the clinical
course of this highly malignant tumor. GBM therefore requires
additional forms of therapy to prolong the lifespan and quality of
life of patients. Immunotherapy is now emerging as a novel fourth
option for clinicians.
Immunotherapy stimulates and teaches the patient’s immune
system to recognize and eradicate malignant tumor cells. If
successful it has the added advantage of generating a memory
response to prevent tumor reoccurrences after cessation of treat-
ment. Our immune system has evolved to protect our body by
eliminating pathogens and abnormal cells with minimal damage
to healthy tissues. It is complex and has multiple levels of
regulation to guarantee the appropriate balance between immune
activation and immune suppression. Over the last two decades the
fundamentals of this regulation have become more clear.
It has been amply shown that the immune system can prevent
the emergence and growth of cancer. For example, an adaptive
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tumors as evidenced by in situ analysis of tumor-infiltrating
immune cells.
1,2 Also, in ovarian cancer the presence of intra-
epithelial tumor infiltrating lymphocytes is associated with
prolonged clinical remission and improved survival.
3 Similar
observations have been made for other tumors, such as renal
carcinoma,
4 prostate cancer
5 and breast carcinoma.
6 These
observations in patients are further supported by the observations
in experimental systems that an impaired immune system is less
able to protect the host against the development of spontaneous
and chemically-induced tumors.
7-9 In addition, individuals with
cancer sometimes develop spontaneous reactivity against the anti-
gens of the tumor.
10 Hence, it can be concluded that tumors can
be recognized and eliminated as a result of natural tumor-specific
immune responses that develop in the host.
The observations that the capacity to mount natural immune
responses is linked to improved survival supports the concept
to develop immune activating tumor vaccines, stand alone
immune activators, or biological response modifiers. Presently,
such strategies are tested in clinical trials for the treatment
of different types of solid tumors, including glioblastoma, as
recently reviewed by Hofman and coworkers.
11 To date, these
approaches have provided only modest clinical results. Never-
theless, they have shown promise by successfully generating
antigen specific effector T cells capable of reacting with the
tumor, and significant survival advantage or improved quality of
life in subgroups. Remarkably, effector immune cells may fail
to produce tumor regression because newly triggered and
successfully expanded tumor-specific lymphocytes are actively
inhibited within the draining lymph nodes or upon entrance
into the tumor. In recent years it has become well-established
that many tumors, including GBM, use various mechanisms
of immune suppression or evasion, including immunediting, and
the generation of T regulatory (Treg) and myeloid derived
suppressor cells (MDSC).
12
These cells act to inhibit the beneficial effects of immune
activation
13 by direct cell contact mechanisms or by secretion of
inhibitory molecules, such as IL-10, and TGFβ.
14,15 As a result,
the suppression of immunity in tumors may present a major
challenge to clinicians interested in using tumor vaccines or
other methods of immune activation to treat tumors at the
time of diagnosis. Immunotherapy may be further complicated
in situations where the immune system promotes tumor
development by selecting for tumor escape variants with reduced
immunogenicity.
16
Hence, successful immunotherapy for the treatment of solid
tumors may require two entirely different steps: (1) the use of
potent immune activators such as single immunostimulants or
tumor vaccines comprising suitable adjuvants; and (2) reagents
that can reverse immune suppression induced by the tumor.
In the last two decades there has been a strong interest in using
toll-like receptor (TLR) agonists as immunostimulants and
adjuvants for therapeutic vaccines because of their stimulatory
effects on innate immune responses which precedes the shaping
of adaptive immune effector and memory cells.
17,18 TLRs are so-
called pattern recognition receptors that are found on a variey of
innate immune cells
17 and able to recognize pathogen-specific
molecular patterns (PAMPS). They discriminate these PAMPS
from invading pathogens as non-self molecules, which represent
a signal for the receptor-expressing immune cells to become
activated and produce pro-inflammatory cytokines and costimu-
latory molecules resulting in recruitment and activation of
immune cells.
The imidazoquinoline-based small molecules imiquimod and
resiquimod are synthetic ligands that have been shown to activate
human TLR 7 and 8, and TLR7 in mice and rats. TLR8 is not
functional in mice. These TLRs also recognize viral and synthetic
single-stranded RNAs. The TLR7/8 agonist R837 (imiquimod)
has been licensed as a key ingredient in Aldara cream for the
topical treatment of genital warts, basal cell carcinoma and
bladder cancer.
19-21 In mouse studies, imidazoquinolines were able
to act as adjuvants promoting adaptive immune response to
co-administered prophylactic antigens.
22,23 This observation is
in line with the notion that single-stranded RNA induces an
antigen-specific immunity characterized by a potent cytotoxic
T-cell response.
24
However, very little is known about how systemically admini-
stered TLR7/8 agonists affect immune responses in general and
anti-tumor immunity to glial brain tumors. Interestingly, Xiong
and Ohlfest recently showed that topical imiquimod (Aldara)
applied on the skin has therapeutic and immunomodulatory
effects against intracranial tumors in a mouse model.
25 Weekly
application increased survival of mice against implanted syngeneic
GL261 glioma tumors. Resiquimod is related to imiquimod, as
they are both synthetic small molecules that activate Toll-like
receptor (TLR) 7.
26
In the present study, we investigated the anti-tumor immune
effects of parenterally injected resiquimod (R848) in a CNS-1
glioma model in immunocompetent Lewis rats. This model
represents a valuable in vivo system for preclinical studies because
of histopathological and pathological features which highly
resemble human GBM.
27 Our results show that TLR7/8 agonist
resiquimod (R848) affects immune responses leading to growth
arrest of large established glioma tumors, and that R848 treat-
ment, at the concentrations used, does not inhibit CNS-1 tumor
growth directly. Remarkably TLR7/8 activation by R848, as a
therapeutic stand-alone therapy, is able to reject smaller estab-
lished CNS-1 tumors, leading to solid, immunological memory
against tumor rechallenge. Hence, this TLR7/8 activation
approach provides a new opportunity for rational therapeutic
immune interventions based on strengthened anti-tumor immune
responses that may translate into successful clinical outcome in
patients affected by glioblastoma.
Results
Therapeutic adminstration of the TLR7 immunostimulant
resiquimod arrests growth of large (35-day old) CNS-1 tumors.
We sought to determine immunotherapeutic strategies for
controlling the malignant growth of syngeneic CNS-1 glioma
tumor cells in Lewis rats using the newly described small molecule
TLR7/8 agonist resiquimod, also referred to as R848.
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developed large syngeneic CNS-1 tumors, would benefit from
R848 treatment (100 mg/kg, 30 mg/dose), we started to treat
established, large five week-old, 10- 20,000 mm
3, CNS-1 tumors,
at 38 days after tumor implantation. Indeed, resiquimod treat-
ment was able to arrest or slow tumor growth in 2/3 animals, as
shown in Figure1, however, complete regression of these large
tumors was not noted within the observation period.
We next decided to investigate the antitumor activity of
resiquimod against lower tumor burden in rats with less advanced
CNS-1 tumors. In a subsequent pilot dose-finding experiment
we noticed a dose-dependent inhibition of CNS-1 tumor
growth, when treatment was started earlier at day 10 after tumor
implantation. Injection of a low dose of immunostimulatory
resiquimod (3.3 mg/kg = 1 mg/dose) did not inhibit CNS-1 tumor
growth, while a higher dose of either 10 or 50 mg/dose,
representing 33.3 and 166.6 mg/kg respectively, clearly evoked
reduction in tumor growth (data not shown). We therefore
decided to test robustness of this protective treatment in a larger
experiment. Figure2A shows that administration of R848, at a
dose of 100 mg/kg (this is about 30 mg/ dose), when given three
times per week (Monday, Wednesday and Friday) profoundly
reduces tumor growth, relative to a control group receiving
no treatment (p , 0.001). We stopped the therapeutic weekly
treatment regimen after day 42 (week 6) and further continued
to monitor tumor growth.
Therapeutic administration of high dose cyclophosphamide
alone or in combination chemo-immunotherapy of CY with
resiquimod protects against CNS-1 tumor growth. We next
examined whether resiquimod immunotherapy combined with
chemotherapy further improves anti-tumor immunity. Hence,
in a parallel arm of the same animal experiment we investigated
the therapeutic efficacy of the cytotoxic alkylating agent cyclo-
phosphamide (CY), given once every two weeks, which is a well-
know direct cytostatic antitumor agent, but has also been shown
to mediate immune suppression or even tumor regression by
abrogation of immunosuppressive T regulatory cell function.
28 In
addition, we tested the combined treatment of CY plus R848 to
investigate beneficial synergy of CY with active immunotherapy,
as a chemo-immunotherapy variant.
29,30 Figure2 shows that
inhibition of CNS-1 glioma tumor growth was observed for a
group which received CY alone (Fig.2B) or resiquimod in
conjunction with CY at a 100 mg/kg dose (Fig.2C;p, 0.001).
The combined administration of CY and R848 seemed to further
inhibit tumor development as noted by earlier tumor regression.
Poly I:C injected in a similar regimen, at a dose of 30 or 50 mg,
did not inhibit CNS-1 growth (data not shown). A lower dose of
30 mg/kg of CY alone also failed to inhibit tumor growth.
Figure1. Indication of inhibition of established large CNS-1 tumors in
Lewis rats (n = 3) treated with resiquimod starting at day 38. Individual
growth as a function of time after implanation is shown for each
individual animal. The arrow indicates the start of resiquimod treament.
Figure2. Therapeutic administration of TLR7/8 agonist resiquimod
strongly inhibits tumor growth. CNS-1 tumor development after
implantation in groups of rats (n = 8) treated with either resiquimod (A),
Cyclophosphamide (B) or a combination of resiquimod and cyclopho-
sphamide (C). Individual growth as a function of time is shown. The
stippled lines show individual tumor growth of untreated controls.
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To examine whether parenterally injected resiquimod may have
been able to directly affect CNS-1 tumor growth we tested the
cytotoxicity of resiquimod in vitro, in parallel to cyclophosp-
hamide and poly I:C, a prototype TLR3 agonist. Figure3 shows
a direct cytotoxicicty of cyclophosphamide when used at high
dose, and no apparent direct growth inhibition by resiquimod,
at concentrations reflecting the in vivo dose. The effective
concentration of resiquimod of 30 mg/dose used in vivo is not
directly cytotoxic in vitro and is therefore very unlikely to evoke
direct contralateral tumor killing, while the in vivo concentration
of 100 mg/kg (30 mg/dose) is clearly cytotoxic for CNS-1 cells
cultured in vitro (200,000 cells /well).
CNS-1 glioma cells do not express TLR 7/8. We checked
expression of TLR7 and TLR8 by CNS-1 cells using RT-PCR,
but where unable to detect receptor expression, while expression
of both receptors could be detected in rat spleen tissue (Fig.4).
Glioma tumors cured by resiquimod therapy alone evoke
immunological memory when rechallenged with syngeneic
CNS-1 tumor. To examine whether immunocompetent Lewis
rats, which had rejected CNS-1 cells as a result of resiquimod
treatment, had developed immunological memory against CNS-1
tumor cells, they were re-challenged at day 49 after the first tumor
implantation (one week after treatment arrest and wash out of
R848) using a tumor dose of CNS-1 which evoked tumor growth
in naive age-matched control rats.
As shown in Figure5 all recipients of R848 therapy which
had eliminated the first CNS-1 tumors, completely rejected the
secondary CNS-1 challenge, with no evidence of measurable
secondary tumor growth (Fig.5B,p, 0.01), while the same dose
of CNS-1 tumor cells induced reproducible tumor development
in all untreated age-matched Lewis rats (Fig.5A). This observa-
tion was confirmed in a subsequent experiment as evidenced by a
complete rejection of a secondary tumor challenge, after cessation
of treatment for a period of three months, in a group of four R848
treated Lewis rats, which had rejected the first CNS-1 tumor.
Again this additional tumor challenge evoked progressive tumor
growth in naive age-matched controls.
Glioma tumors controlled by treatment with CY alone or by
CY-resiquimod combination therapy fail to evoke immuno-
logical memory against rechallenge with syngeneic CNS-1
tumor. Lewis rats that had initially rejected CNS-1 cells as a
result of CY treatment alone, or after CY-R848 combination
treatment, were tested for immunological memory against CNS-1
tumor cells, by a re-challenge at day 49 after the first tumor
implantation. Upon secondary tumor challenge both, the CY only
treated, as well as the CY-R848 combination treated hosts,
displayed an initial inhibition of secondary tumor development
(Fig.5C and D,p, 0.01 and , 0.05, respectively), but
eventually progressive CNS-1 growth was noted in most animals.
This indicated a deleterious effect of the CY on the endogenous
Figure3. CNS-1 cells (200,000 cells per well) were exposed for 24 hours to increasing concentrations per well of either resiquimod (A), or CY (B). Viability
was measured (in triplicate) in a standard (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) bromide assay, and was expressed as a percentage
of viability measured for cells cultured in medium only (control). Representative data of two experiments are shown.
Figure4. Lack of detection of TLR 7 and TLR 8 expression in both rat
glioma CNS-1 cells and murine glioma GL261 cells. However, in rat
spleen tissue, used as positive control, expression of both TLR7 and TLR8
can be detected.
www.landesbioscience.com OncoImmunology 301Figure5. Individual CNS-1 tumor development as a function of time after secondary tumor implantation (A–D) in groups of rats (n = 8) treated either
with Resiquimod alone (B), Cyclophosphamide alone (C) or a combination of Resiquimod and cyclophosphamide (D). The CNS-1 implanted, untreated
age-matched group is shown in (A) (n = 4). Mean tumor growth of (A) is shown as a stippled line for the untreated control group in (B–D). (E–G) show the
growth of the recurrent individual primary CNS-1 tumors at the original inoculation site, for the resiquimod treated (E), Cyclophosphamide treated (F)
and combination group (G) at the days post primary tumor challenge.
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to and keeping the CNS-1 tumor cell growth suppressed. Further
substantiating this conclusion, the CY-treated rats, alone as well as
in combination therapy, also showed a recurrence of their primary
tumor, which apparently was not completely resolved (Fig.5F
and G, respectively). In both groups, seven out of eight animals
showed progressive tumor growth.
Safety. In our studies we did not observe any signs of toxicity in
rats treated with the systemic resiquimod.
Discussion
In the present study we demonstrate that immunotherapy based
on the innate immune cell activator resiquimod, is effective as a
treatment modality for eradication of established CNS-1 glioma
tumors.
OurCNS-1gliomacell implants aresyngeneic, haplotypeRT-1
l,
for Lewis rats and represent an excellent in vivo glioma model,
because of its glial phenotype,reproducible in vivo growth rates and
histological features that closely resemble human glioma.
31 It has
been demonstrated that CNS-1 tumor cells are immunoreactive for
glial fibrillary acidic protein (GFAP), S100 and vimentin, as well as
neuronal adhesion molecule, retinoic acid receptor a, intracellular
adhesion molecule and neuron specific enolase.
31 This model
thereforeprovides an excellentin vivo model inwhich toinvestigate
immunotherapeutic intervention strategies against glioblastoma
multiforme in immunocompetent hosts.
Natural immune responses against glioma tumors are often
elicited as demonstrated by histological evidence of local inflam-
mation and tumor-specific lymphocytes, likely directed against
tumor specific antigens. However, the GBM tumor micro-
environment is characterized by the presence of a variety of
immunosuppressive cells and their inhibitory products, which
may eventually result in the escape of the tumor from immune
surveillance.
32-35 However, when an effective therapeutic dose of
resiquimod was injected three times per week, we observed a
dramatic reduction in tumor volume. While most untreated or
control tumor-bearing animals had to be sacrificied, either due
to massive tumor volumes or due to ulceration of the tumor,
the groups receiving a dose of more than 10 mg resiquimod per
injection eventually showed complete regression of the tumor
volumes. When therapeutic treatment was arrested, at day 49
after implantation, the tumor had shrunk to minute or non-
measurable sizes. In vitro studies revealed that resiquimod (0.01
or 0.1 mg/ml), in contrast to CY, did not directly inhibit CNS-1
tumor cell growth.
These results may seem contradictory with other data showing
that when tumor cells express TLR7/8, activation of this TLR
type leads to cell survival and chemo resistance.
36 We have
therefore checked expression of TLR7/8 by CNS-1 cells by RT-
PCR, but where unable to detect receptor expression by PCR.
However, even if TLR7/8 activation by resiquimod would have
stimulated tumor growth the net effect in vivo would apparently
still be tumor regression.
Interestingly, all rats proved immune to re-challenge with
CNS-1 glioma cells (Fig.5) as evidenced by complete inhibition
of tumor development. Immune memory against rechallenge was
confirmed for rats which received the additional tumor inocula-
tion even after three months of treatment arrest, while naive
rats developed tumors. In view of the short half-life of the
imiquimod family members of only few hours it is very unlikely
that resiquimod had some remnant activity after a three month
resting period before administration of a tumor rechallenge. The
complete inhibition of secondary tumor growth suggest that
immunotherapeutic treatment during the first tumor growth,
using resiquimod, a known innate immune response agonist
activating TLR7/8, results in tumor regression that results in the
development of T cells with immune memory. Hence this innate
immune triggering acts as an in situ therapeutic vaccine, alerting
the adaptive immune system to recognize and eliminate the
syngeneic secondary CNS-1 brain tumor. In future studies we
will set out to decipher the exact mechanism underlying this
intriguing observation of in situ immune memory priming.
In addition, we evaluated the effects of CY on CNS-1 tumor
development. Cyclophosphamide (CY), although primarily used
as cytotoxic therapy and expected to suppress the immune system,
has been shown to abrogate immunosuppressive T reg function,
and beneficially synergize with active immunotherapy when used
at an appropriate dose and timed correctly.
29,37,38
CNS-1 tumors regressed, as a result of CY treatment, and even
faster after combined CY-R848 chemo-immunotherapeutic treat-
ment. Importantly, the administration of CY, after the animals
had developed immunity to CNS-1, was deleterious (Fig.4). The
explanation for why, after tumor rechallenge, the animals that
were treated with CY only or by the CY-R848 combination were
not able to inhibit secondary tumor development relates to the
CY also causing damage to the CTL that had developed in situ
at the beginning of the treatment. Additionally, it provides an
explanation for why the CY-treated rats also exhibited recurrence
of the primary tumor. These data highlight the need to carefully
arrange the administration of combined therapeutics involving
cytotoxic chemotherapeutic agents with immunotherapeutic
agents so one agent does not interfere with the effects derived
from the other. However, the delay in tumor growth after
rechallenge of the cyclophosphamide group, suggests that there is
an immune effect, which is most likely dependent on T cells,
although a memory response by B cells cannot be excluded
formally. In both scenarios T cells are necessary for T help and
likely also for T-cell effector function. The effect of T cell deple-
tion will be subject of follow-up studies addressing the biological
mechanism of action responsible for rechallenge immunity.
These results provoke two intriguing questions. How does R848
eradicate CNS-1 tumors, and how does immune memory develop
during this treatment? In addition, it is of interest to know how CY
hampers antitumor immunity. The exact mode of action and
associated immune pathway responsible for the observed resiqui-
mod-mediated anti-tumor immunity needs to be defined in
detailed follow-up studies. Most likely resiquimod-based immu-
notherapy is able to activate a spontaneous, natural, innate anti-
tumor immune response, that under normal circumstances is
unable to control tumor growth, likely as a result of delayed or
actively suppressed immune control. Non-specific immune attack
www.landesbioscience.com OncoImmunology 303of the tumor evoked by TLR7/8 activating resiquimod, but not by
poly I:C treatment activating TLR3 (data not shown), may release
tumor antigens into the surrounding tumor environment which are
sampled by locally attracted antigen presenting cells and which
allow presentation to and priming of adaptive immune lympho-
cytes, in the draining lymph nodes. Alternatively, or in parallel, an
in situ “vaccination” occurs as a result of R848 therapy. TLR7
activation by the related imiquimod causes human and rodent
dendritic cells to become tumoricidal.
39 Eventually, a sufficient
number of tumor-specific naive adaptive immune cells, such as
cytolytic T cells, are triggered and expanded in draining lymph
nodes as a result of parenteral R848 immunotherapy and enabled
by activated antigen-presenting cells. These presumed cytolytic T
cells selectively recognize and eliminate the tumor and provide
immunological memory, as illustrated by the rejection of
secondary tumor cell implants. However, dedicated follow-up
studies need to address to involvement of anti-tumor killer
macrophages or NK cells, or IFNs for the resiquimod-induced
glioma growth regression and immune memory.
In conclusion, our data show that injection of the innate
immune cell receptor agonist resiquimod as a therapeutic TLR7/8
activating stand-alone therapy, is able to cure established CNS-1
tumor growth in Lewis rats. They suggest that immunother-
apeutic parenteral treatment of established glioma tumors by
resiquimod, as defined in the protocol, significantly improves
anti-brain tumor immunity in a way that leads to immune
memory, which is superior to CY treatment alone. Our studies
have thereby identified a promising novel antitumor immu-
notherapy which may lead to clinical benefit.
Materials and Methods
Tumor model. Rat CNS-1 cells (2  10
5 cells/200 ul) were
implanted subcutaneously (SC) using a 21 gauge needle into the
right flank of 8–12 week-old (300 g body weight) male Lewis
rats. For each treatment group and control, 4–8 rats/group were
used. The same tumor implantation procedure was performed
during re-challenge experiments, on the contralateral side, for
rats which had controlled the tumor growth after first exposure. All
animal studies were approved by an independent ethical committee.
Monitoring tumor growth. The sizes of the CNS-1 tumor
volumes were measured using a caliper three times per week on
Mondays, Wednesdays and Fridays to monitor the effects of each
treatment group.
Completion of experiment. Tumor implanted rats were
sacrificed if they showed unfavorable signs of discomfort, as defined
by the ethical committee. For example if they appeared moribund
due to weight loss, lethargy, ruffled fur, or when tumors showed
ulceration. A mixture of Rompun and ketamine was used for
anesthesia,followedbyadoseofsodiumpentobarbitalforeuthansia.
Chemicals and reagents. Immunomodulators and potentiators.
Rats were subcutaneously (SC) injected in the flank, contralateral
to the tumor-implanted side, with resiquimod (R848) (purchased
from Invivogen, catalog number tlrl-r848), a Toll-like receptor
7/8 agonist, in a range of 3.3–166.6 mg/kg, corresponding to
1–50 mg/dose, three times per week on Mondays, Wednesdays
and Fridays. Resiquimod(R-848, S-28463) was shown to be more
soluble and more potent in inducing cytokine expression than its
family member imiquimod which has a half-life of 2–3hi n
humans
40.
In a parallel arm of the experiment we evaluated the effect
of cyclophosphamide administration on CNS-1 glioma develop-
ment. Cyclophosphamide (CalBiochem, 239785) was given at
30–100 mg/kg. CY was injected once every two weeks on Fridays.
Cytotoxicity assay. The direct cytotoxicity of resiquimod, CY
and Poly I:C (Invivogen, Tlrl-pic, tlrl-pic-5), which was included
as a reference TLR-3 agonist, was determined by exposing CNS-1
cells at a concentration of 200,000 cells per well in a 96-well
plate in DMEM culture medium (30-2002, ATCC), supple-
mented with 10% fetal bovine serum (FBS; Lonza, DE14-801E),
for 24 h. The viability of CNS-1 cells, measured in triplicate,
was measured in a standard (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT) bromide assay, absorbance was
read at 590 nm, and was expressed as a percentage of viability
measured for cells cultured in medium only.
TLR 7 and TLR 8 detection by RT-PCR. Samples collection.
Normal spleen tissue was obtained by surgical resection from a
male non-treated Lewis rat and cut in pieces of 1 mm
3 with a
sterile surgical blade. CNS-1 and GL-261 cell lines were cultured
as described above and a pellet of 1  10
6 cells was used. Cells or
tissue sample were put in lysis buffer using the SV Total RNA
Isolation System (Promega Corp., Leiden, The Netherlands).
RNA extraction and reverse transcription. After extraction of
total RNA it was reverse-transcribed by using the Thermo-
script RT-PCR System (Life Technologies, Inc.) as previously
described.
41
Oligonucleotide primers used for PCR amplification: Primers
for the PCR amplification were obtained by Real Time Primers
LLC, according to successful approach for TLR-7,
42 or as
customized primers for TLR-8 obtained from Real Time
Primers LLC.
PCR. PCR was performed according to the manufacturer’s
recommendations, with Platinum
1 PCR SuperMix (Life
Technologies, Inc.). Aliquots of the RT products were subjected
to PCR in a total volume of 50 ml, with 100 nM adequate paired
primers. PCR products were visualized on a 2% agarose gel with
GelRed
TM Nucleic Acid Gel Prestaining Kit (Biotium), visualized
on an UV transilluminator and photographed using a Canon
Powershot G10 photograph, equipped with a conversion lens 032
LA-DC58K.
Statistical analysis. ANOVA followed by the students t-test
was used to compare groups, *p value of , 0.05, **p , 0.01,
***p , 0.001, considered statistically significant.
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